Phase 2 N=26 A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)
Ulcerative Colitis
Primary: Pharmacokinetics (PK): Clearance of Mirikizumab — 0.000190 Liters per hour per kilogram (L/hr/kg)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=11 Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting
Keratoconus · Ocular Surface Disease · Pellucid Marginal Corneal Degeneration
Primary: Central Corneal Clearance — 354.29 microns
Phase 2 N=885 A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults
Seasonal Influenza
Primary: Number of Participants With Solicited Local and Systemic ARs — 12; 43; 22; 16 Participants
Phase 2 N=60 Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma
CNS Cancer · CNS BRAIN
Primary: Progession Free Survival — 85.7 % of participants without progression
N/A N=80 Cook Balloon vs Dilapan-S for Outpatient Cervical Ripening
Induced; Birth
Primary: Change in Bishop Score — 3.0; 3.0 score on a scale — p=0.91
Phase 3 N=37 Aspirin for Exercise in Multiple Sclerosis (ASPIRE)
Multiple Sclerosis
Primary: Time-to-exhaustion — 551.7; 331.6; 578.2 seconds
Phase 2 N=9 Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
Wilson Disease
Primary: Mean Daily Copper Balance: Day 1 Through Day 8 — 0.8025; 0.3062 milligrams/day
Phase 2 N=24 Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Pancreas Neoplasm Malignant Resectable
Primary: Frequency of R0 Resection — 11; 2 Participants
Phase 4 N=22 Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Palmoplantar Psoriasis · Plaque Psoriasis
Primary: Palmoplantar Physician Global Assessment (ppPGA) — 3.47; 2.24 score on a scale
N/A N=16 Bilateral Priming for Upper Extremity Hemiparesis in Older Adults
Stroke, Upper Extremity Hemiparesis
Primary: Change Score of Chedoke Arm and Hand Activity Index Nine (CAHAI 9) Baseline to Follow-up (2 Timepoints) — 6.69; 5.03 score on a scale
N/A N=1,484 Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
Chronic Myeloid Leukaemia
Primary: Overall Survival Rate: All Participants — 77.1 Percentage of participants
Phase 2 N=29 Platelet-Rich Plasma Therapy for Patellar Tendinopathy
Patellar Tendinitis
Primary: Change in Measure of Pain Level: VISA-P Score — 32.2; 46.3; 43.2; 52.5 score on a scale
Phase 2 N=225 Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal
Opioid Withdrawal
Primary: Peak SOWS Scores at Baseline and Over Time — 3.6; 5.2; 6.0; 4.7 score on a scale
Phase 2 N=108 A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Percent Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16 — -58.4; -39.4; -21.5 Percent change — p=0.0103
N/A N=68 Feasibility of a Yoga Intervention in Sedentary African-American Women
Sedentary Behavior
Primary: Number of Participants Recruited (Feasibility) — 319; 69 Participants